Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?

Eli Lilly and Company and Precision BioSciences, Inc. announced today that they have entered a research collaboration and exclusive license agreement to use Precision’s ARCUS genome editing platform to research and develop potential in vivo therapies for a series of genetic disorders. Specifically, the companies will be focusing on Duchenne muscular dystrophy (DMD), along with two other undisclosed gene targets. ARCUS will give them the opportunity to make a variety of efficient edits, enabling a range of therapeutic editing.